diclofenac has been researched along with Hand-Foot Syndrome in 2 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Hand-Foot Syndrome: Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy." | 9.51 | Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). ( Batra, A; Cheung, WY; Gogia, A; Gupta, I; Gupta, N; Kumar, A; Pandey, RM; Pramanik, R; Prasad, CP; Santhosh, A; Sharma, A, 2022) |
| "Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy." | 5.51 | Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). ( Batra, A; Cheung, WY; Gogia, A; Gupta, I; Gupta, N; Kumar, A; Pandey, RM; Pramanik, R; Prasad, CP; Santhosh, A; Sharma, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santhosh, A | 1 |
| Kumar, A | 1 |
| Pramanik, R | 1 |
| Gogia, A | 1 |
| Prasad, CP | 1 |
| Gupta, I | 1 |
| Gupta, N | 1 |
| Cheung, WY | 1 |
| Pandey, RM | 1 |
| Sharma, A | 1 |
| Batra, A | 1 |
| Thai, KJ | 1 |
| Ralph, C | 1 |
| England, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for diclofenac and Hand-Foot Syndrome
| Article | Year |
|---|---|
Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Topics: Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; H | 2022 |
1 other study available for diclofenac and Hand-Foot Syndrome
| Article | Year |
|---|---|
Treatment of Cabozantinib-Related Palmar-Plantar Erythrodysesthesia With Topical Sildenafil, Diclofenac, and Gabapentin Cream: A Case Report.
Topics: Administration, Cutaneous; Aged; Anilides; Carcinoma, Renal Cell; Diclofenac; Gabapentin; Hand-Foot | 2020 |